Clinical Inquiries

Is red-yeast rice a safe and effective alternative to statins?

Author and Disclosure Information

 

References

Total adverse events in this study were similar for red-yeast rice and placebo (2.1% vs 1.2%, respectively; P>.05). They included gastrointestinal discomfort, allergic reactions, myalgias, edema, erectile dysfunction, and neuropsychological symptoms.

Red-yeast rice is similar to placebo or another statin in statin-induced myalgia

In patients with known coronary artery disease and dyslipidemia, therapy with red-yeast rice extract is linked to reductions in CHD mortality and myocardial infarction similar to statins. In a small community-based trial of 62 adults with dyslipidemia and a history of statin-induced myalgia, investigators randomized patients to receive either red-yeast rice extract at 1800 mg (with 3.1 mg lovastatin) or placebo twice daily for 24 weeks.4 Patients’ weekly self-reports of pain (on a 10-point scale) were skewed at baseline (1.4 in the red-yeast rice group vs 2.6 in the placebo group; P=.026) but similar at 12 weeks (1.4 with red-yeast rice vs 1.9 with placebo; P=.30) and 24 weeks (1.2 with red-yeast rice vs 2.0 with placebo; P=.120).

An RCT of 43 adults with dyslipidemia and history of statin intolerance compared red-yeast rice extract (2400 mg, with 10 mg lovastatin) with pravastatin (20 mg) dosed twice a day.5 At the end of 12 weeks, mean self-reported pain scores (on a 10-point scale) were similar (1.4 with red-yeast rice vs 1.1 with pravastatin; P=.82), as were discontinuation rates because of myalgia (5% with red-yeast rice vs 9% with pravastatin; P=.99).

RECOMMENDATIONS

A narrative review of alternative therapies for heart failure and hypercholesterolemia states that red yeast rice may be a cost-saving option for hypercholesterolemia in patients who can’t afford other medications (purchased mostly online, cost $8-$20/month for a dosage equivalent to lovastatin 20 mg/d).6

A ConsumerLab review of red yeast rice products available since the FDA ban in 2011 tested products marketed in the United States and found variable amounts of lovastatin.1,7 The group determined that labeling was a poor guide to lovastatin content, which ranged from 0 to 20 mg per daily dose, and that the products may not have been standardized. The group concluded that therapeutic effects weren’t predictable.

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

ACOG outlines new treatment options for hypertensive emergencies in pregnancy
MDedge Family Medicine
Unnecessary stress tests in ED leading to overdiagnosis
MDedge Family Medicine
Icatibant rapidly resolved ACE inhibitor–induced angioedema
MDedge Family Medicine
Broad application of JNC-8 would save lives, reduce costs
MDedge Family Medicine
What is the best beta-blocker for systolic heart failure?
MDedge Family Medicine
Statins found to have a survival benefit in colorectal cancer
MDedge Family Medicine
Renal denervation therapy: What’s next
MDedge Family Medicine
Most cardiologists misstep on aspirin in ACS
MDedge Family Medicine
Would a cholesterol medication have made a difference? … More
MDedge Family Medicine
Just call me coach
MDedge Family Medicine

Related Articles

  • Applied Evidence

    Statin adverse effects: Sorting out the evidence

    Studies have assessed the incidence of everything from myopathy to diabetes and cataracts, but findings have been inconsistent. Here’s help in...

  • Applied Evidence

    Which CAM modalities are worth considering?

    This review—with a handy at-a-glance guide—examines 8 modalities, the level of evidence behind them, and the adverse effects you’ll need to keep...